9-year follow-up from the RADICALS-HD trial

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University and Research Fellow at Dana-Farber Cancer Institute, shared a post on X about a recent paper by Chris C. Parker et al., commenting:

“A 9-year follow-up from the RADICALS-HD trial showed no significant difference in metastasis-free survival among prostate cancer patients receiving no Androgen Deprivation Therapy (ADT), 6-month ADT, or 24-month ADT after postoperative radiotherapy.

• 492 patients.
• 10 years, 80% (no ADT), 77% (6-month ADT), and 81% (24-month ADT) remained metastasis-free.

Despite the lack of Metastasis Free Survival (MFS) improvement, the trial underscores the need for future research focused on high-risk patients where treatment innovation is most needed.”

Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047) published in ScienceDirect.

Additional information

Source: Emre Yekedüz/X